Randomized phase III trial in elderly patients with previously untreated symptomatic Multiple Myeloma comparing MP-Thalidomide (MP-Thal) followed by thalidomide maintenance versus MP-Lenalidomide (MP-Len) followed by maintenance with lenalidomide.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Jun 2017
At a glance
- Drugs Lenalidomide (Primary) ; Melphalan; Prednisone; Thalidomide
- Indications Multiple myeloma
- Focus Pharmacogenomic; Therapeutic Use
- 25 Jun 2017 Results of validation of the SKY92 gene expression classifier and rISS in patients from this trial presented at the 22nd Congress of the European Haematology Association.
- 22 Jan 2016 Results published in the Blood
- 20 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by Netherlands Trials Register.